Intravitreal faricimab improved visual acuity and macular thickness, allowing treatment interval extension in 61-81% of treatment-naïve and 36-78% of previously treated eyes.
Systematic Review (n=6,054)
Does intravitreal faricimab improve visual acuity and macular thickness in eyes with diabetic macular edema?
Real-world evidence suggests faricimab improves visual outcomes in diabetic macular edema while allowing for extended treatment intervals.
BACKGROUND: Diabetic macular edema (DME) is a prevalent exudative maculopathy, and anti-vascular endothelial growth factor (anti-VEGF) therapy is the first-line choice for treatment. Faricimab, a novel anti-VEGF and anti-angiopoietin-2 bispecific agent, has recently been approved for the treatment of DME. In this study, we systematically reviewed the real-world evidence of the efficacy of faricimab for the treatment of DME. METHODS: We searched 11 databases for eligible studies. Study selection and data extraction were made independently by two authors in duplicate. Eligible studies were reviewed qualitatively. RESULTS: We identified 10 eligible studies that summarized data from a total of 6054 eyes with a mean follow-up of between 55 days and 12 months. Five studies reported outcomes in a population of both treatment-naïve and previously treated eyes, and five studies reported outcomes exclusively in relation to eyes that were previously treated. Faricimab improved the best-corrected visual acuity and macular thickness. The extension of the treatment interval was possible in 61-81% of treatment-naïve eyes and 36-78% of previously treated eyes. CONCLUSIONS: Faricimab for DME yields clinical outcomes similar to those known from previous anti-VEGF treatments but with extended treatment intervals, thus lowering the burden of therapy for patients. Long-term real-world studies are warranted.
Nasimi et al. (Wed,) conducted a systematic review in Diabetic Macular Edema (n=6,054). Intravitreal Faricimab was evaluated on Best-corrected visual acuity, macular thickness, and extension of treatment interval. Intravitreal faricimab improved visual acuity and macular thickness, allowing treatment interval extension in 61-81% of treatment-naïve and 36-78% of previously treated eyes.